(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 33.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.26%.
Intellia Therapeutics's revenue in 2024 is $45,967,000.On average, 13 Wall Street analysts forecast NTLA's revenue for 2024 to be $5,679,698,718, with the lowest NTLA revenue forecast at $3,645,880,216, and the highest NTLA revenue forecast at $10,006,870,547. On average, 12 Wall Street analysts forecast NTLA's revenue for 2025 to be $8,688,880,583, with the lowest NTLA revenue forecast at $914,212,692, and the highest NTLA revenue forecast at $21,331,629,480.
In 2026, NTLA is forecast to generate $10,841,546,735 in revenue, with the lowest revenue forecast at $2,031,583,760 and the highest revenue forecast at $17,870,826,545.